LB Pharmaceuticals, Inc. (LBRX) Stock Statistics & Valuation Metrics

LB Pharmaceuticals, Inc. has a market cap or net worth of ―. The enterprise value is ―.

LB Pharmaceuticals, Inc. has 25,299,103 shares outstanding. The number of shares has decreased by -2.65% in one year.

LB Pharmaceuticals, Inc.’s return on equity (ROE) is 0.67 and return on invested capital (ROIC) is -250.20%.

The current PE Ratio of LB Pharmaceuticals, Inc. is ―. LB Pharmaceuticals, Inc.’s PEG ratio is -0.00110.

In the last 12 months, LB Pharmaceuticals, Inc. had revenue of 0.00 and earned -63.10M in profits. Earnings per share was -17.83.

In the last 12 months, operating cash flow was -9.57M and capital expenditures -47.00K, giving a free cash flow of -9.62M billion.

LB Pharmaceuticals, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―

LB Pharmaceuticals, Inc. upcoming earnings date is Nov 6, 2025, Before Open (Confirmed).

LB Pharmaceuticals, Inc. as a current ratio of 3.56, with Debt / Equity ratio of ―

In the past 12 months, LB Pharmaceuticals, Inc. has paid 1.00K in taxes.

LB Pharmaceuticals, Inc. EV to EBITDA ratio is -0.67, with an EV/FCF ratio of -0.78.

LB Pharmaceuticals, Inc. has $72.13M in cash and marketable securities with $0.00 in debt, giving a net cash position of $72.13M billion.

Gross margin is ―, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for LB Pharmaceuticals, Inc. is $49.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy